A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Irinotecan (Primary) ; Veliparib (Primary)
- Indications Breast cancer; Colon cancer; Hodgkin's disease; Lung cancer; Male breast cancer; Non-Hodgkin's lymphoma; Ovarian cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- 12 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 10 Jun 2017 Biomarkers information updated
- 25 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.